Central nervous system infection and cutaneous lymphadenitis due to Mycobacterium kansasii in an immunocompetent patient [3]

Infection

Volumn 35, Issue 4, 2007, Pages 291-294

  Tabatabaei, N ^a   Stout, J ^b   Goldschmidt Clermont, P ^c   Murdoch, D ^b  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; CIPROFLOXACIN; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ACID FAST BACTERIUM; AGED; ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS LYMPHADENITIS; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; FEVER; HUMAN; IMMUNOCOMPETENCE; LETTER; LYMPHADENITIS; MALE; MILIARY TUBERCULOSIS; MYCOBACTERIUM KANSASII; RECURRENCE RISK; RELAPSE; RISK FACTOR; SERODIAGNOSIS; SKIN BIOPSY; SOMNOLENCE;

AGED; ANTITUBERCULAR AGENTS; CENTRAL NERVOUS SYSTEM BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; HUMANS; ISONIAZID; LYMPHADENITIS; MALE; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM KANSASII; RIFAMPIN; SKIN DISEASES, BACTERIAL;

EID: 34547657493     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6208-7     Document Type: Letter

References (23)

1. Bloch KC, Zwerling L, Pletcher MJ, Hahn JA, Gerberding JL, Ostroff SM, Vugia DJ, Reingold AL: Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998; 129: 698-704.
2. Marras TK, Morris A, Gonzalez LC, Daley CL: Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med 2004; 170: 793-798.
3. Breathnach A, Levell N, Munro C, Natarajan S, Pedler S: Cutaneous Mycobacterium kansasii infection: case report and review. Clin Infect Dis 1995; 20: 812-817.
4. Bergen GA, Yangco BG, Adelman HM: Central nervous system infection with Mycobacterium kansasii. Ann Intern Med 1993; 118: 396.
5. Cegielski JP, Wallace RJ Jr: Infections due to nontuberculous mycobacteria. In: Scheld WM, Whitley RJ, Durrack DT (eds) Infections of the central nervous system. (2nd edn) Lippincott-Raven, Philadelphia 1997.
6. Jacobson KL, Teira R, Libshitz HI, Raad I, Rolston KV, Tarrand J, Whimbey E: Mycobacterium kansasii infections in patients with cancer. Clin Infect Dis 2000; 30: 965-969.
7. Lillo M, Orengo S, Cernoch P, Harris RL: Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev Infect Dis 1990; 12: 760-767.
8. Kotb R, Dhote R, Garcia-Ricart F, Permal S, Carlotti A, Arfi C, Christoforov B: Cutaneous and mediastinal lymphadenitis due to Mycobacterium kansasii. J Infect 2001; 42: 277-278.
9. Lai CC, Lee LN, Ding LW, Yu CJ, Hsueh PR, Yang PC: Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan. J Infect 2005; 53: 77-84.
10. Carpenter JL, Parks JM: Mycobacterium kansasii infections in patients positive for human immunodeficiency virus. Rev Infect Dis 1991; 13: 789-796.
11. Gordon SM, Blumberg HM: Mycobacterium kansasii brain abscess in a patient with AIDS. Clin Infect Dis 1992; 14: 789-790.
12. Huempener HR, Kingsolver WR, Deuschle KW: Tuberculous meningitis caused by both Mycobacterium tuberculosis and atypical mycobacteria. Am Rev Respir Dis 1966; 94: 612-614.
13. Koppel BS, Wormser GP, Tuchman AJ, Maayan S, Hewlett D Jr, Daras M: Central nervous system involvement in patients with acquired immune deficiency syndrome (AIDS). Acta Neurol Scand 1985; 71: 337-353.
14. Monno L, Carbonara S, Costa D, Appice A, Rollo M, Coppola S, Angarano G: Cerebral lesions in two patients with AIDS: the possible role of Mycobacterium kansasii. Clin Infect Dis 1996; 22: 1130-1131.
15. Shafer RW, Sierra MF: Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin Infect Dis 1992; 15: 161-162.
16. Smith MB, Molina CP, Schnadig VJ, Boyars MC, Aronson JF: Pathologic features of Mycobacterium kansasii infection in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med 2003; 127: 554-560.
17. Symington JS, Parenti DM, Keiser J, Simon GL: Disseminated Mycobacterium kansasii infection in HIV-infected patients. In: Programs and abstracts of the 1994 IDSA Annual Meeting. .
18. Wood LE, Buhler VB, Pollak A: Human infection with the yellow acid-fast bacillus; a report of fifteen additional cases. Am Rev Tuberc 1956; 73: 917-929.
19. Marchal G: [Pathophysiology and immunology of tuberculosis]. Rev Mal Respir 1997; 14: S19-S26.
20. Official statement of the American Thoracic Society Diagnosis and treatment of disease caused by nontuberculous mycobacteria Am J Respir Crit Care Med 1997; 156: S1-25.
21. Ahn CH, Lowell JR, Ahn SS, Ahn S, Hurst GA: Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis 1981; 3: 1028-1034.
22. Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP: Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response Thorax 1983; 38: 271-274.
23. Pezzia W, Raleigh JW, Bailey MC, Toth EA, Silverblatt J: Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981; 3: 1035-1039.